Liqi Feng Selected Research

Nausea

1/2022

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liqi Feng Research Topics

Disease

3	Obesity 12/2022 - 09/2021
2	Overweight 12/2022 - 09/2021
2	Body Weight (Weight, Body) 12/2022 - 09/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2022 - 09/2021
2	Stroke (Strokes) 01/2018 - 01/2018
2	Renal Insufficiency (Renal Failure) 01/2018 - 01/2018
1	Morbid Obesity 12/2022
1	Nausea 01/2022
1	Heart Diseases (Heart Disease) 09/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021
1	Chronic Renal Insufficiency 01/2021
1	Lung Neoplasms (Lung Cancer) 12/2020
1	Infections 01/2020
1	Wound Infection (Wound Infections) 01/2018
1	Mediastinitis 01/2018

Drug/Important Bio-Agent (IBA)

3	mazdutideIBA 12/2022 - 09/2021
3	Glucagon Receptors (Glucagon Receptor)IBA 12/2022 - 09/2021
3	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2022 - 09/2021
1	dulaglutideIBA 01/2022

Therapy/Procedure

3	Length of Stay 01/2020 - 01/2018
1	Thoracotomy 01/2021
1	Operative Time 01/2021
1	Segmental Mastectomy (Lumpectomy) 12/2020
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2018